Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Atossa Therapeutics said in an 8-K that it executed a contingent value rights agreement and set a record date. The filing also includes forward-looking statements about a potential priority review voucher and related payments.
Atossa Therapeutics filed an 8-K describing a definitive agreement tied to stapled contingent value rights. The rights are linked to any future priority review voucher monetization and are capped at $50 million.